Patents by Inventor James R. Smith
James R. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170042986Abstract: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as Coh fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitante. Spearation of the solid absorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.Type: ApplicationFiled: March 18, 2016Publication date: February 16, 2017Inventors: Scott M. KEE, Paul I. COOK, James R. SMITH, Robert KLING, Scott A. FOWLER, David WEBER
-
Patent number: 9320783Abstract: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as Coh fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitante. Separation of the solid absorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.Type: GrantFiled: July 17, 2015Date of Patent: April 26, 2016Assignee: CSL Behring L.L.C.Inventors: Scott M. Kee, Paul I. Cook, James R. Smith, Robert Kling, Scott A. Fowler, David Weber
-
Publication number: 20150320846Abstract: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as Coh fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitante. Separation of the solid absorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.Type: ApplicationFiled: July 17, 2015Publication date: November 12, 2015Inventors: Scott M. KEE, Paul I. COOK, James R. SMITH, Robert KLING, Scott A. FOWLER, David WEBER
-
Publication number: 20150301019Abstract: A portable breath analyzer is described including a housing that encloses a probe assembly with two probes: one responsive to the 12CO2 isotopes in a breath sample, and the other responsive to 13CO2 isotopes. Each probe includes a sample cell containing exhaled breath, a correlation cell containing a selected one of the isotopes, and a calibration cell. An IR energy source is associated with each probe. Each IR source causes propagation of infrared energy through the associated sample cell, and into the correlation cell. Gas sample probes may be aligned in series or parallel and respective correlation cells are modified to accommodate the selected probe configuration. MEMS pressure transducers may be utilized in a common wall between adjacent correlation cells to thereby sense a pressure differential caused by the absorption of pulsed IR energy in the correlation cells and to directly indicate an isotopic ratio.Type: ApplicationFiled: April 16, 2014Publication date: October 22, 2015Inventor: James R. Smith
-
Publication number: 20140323405Abstract: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.Type: ApplicationFiled: March 24, 2014Publication date: October 30, 2014Applicant: CSL Behring L.L.C.Inventors: Scott M. Kee, Paul I. Cook, James R. Smith, Robert Kling, Scott A. Fowler, David Weber
-
Patent number: 8722624Abstract: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.Type: GrantFiled: February 28, 2012Date of Patent: May 13, 2014Assignee: CSL Behring LLCInventors: Scott M Kee, Paul I Cook, James R Smith, Robert Kling, Scott A Fowler, David Weber
-
Publication number: 20130039973Abstract: Disclosed herein are immunogenic compositions for producing immediate and sustained immunity to infectious viral and bacteriological pathogens. A univalent immunogenic composition is disclosed comprising an isolated antigen and a polynucleotide formulated into a nanoparticle or liposome. Furthermore, multivalent immunogenic compositions are disclosed comprising multiple univalent immunogenic compositions. Also disclosed, are methods of inducing protective or therapeutic immune responses in individuals comprising administering one or more univalent immunogenic compositions.Type: ApplicationFiled: August 3, 2012Publication date: February 14, 2013Inventors: Henry J. Smith, James R. Smith
-
Publication number: 20120165261Abstract: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.Type: ApplicationFiled: February 28, 2012Publication date: June 28, 2012Applicant: CSL BEHRING LLCInventors: Scott M. Kee, Paul I. Cook, James R. Smith, Robert Kling, Scott A. Fowler, David Weber
-
Patent number: 8124736Abstract: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.Type: GrantFiled: August 13, 2010Date of Patent: February 28, 2012Assignee: CSL Behring L.L.C.Inventors: Scott M Kee, Paul I. Cook, James R Smith, Robert Kling, Scott A Fowler, David Weber
-
Publication number: 20100298753Abstract: This invention uses “targeted apheresis” to treat rheumatoid arthritis patients. “Targeted Apheresis” is a process whereby the RF and immune complexes responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing immobilized IgG. The RF and immune complexes are bound out and the cleaned blood is returned to the patient Removal of circulating RF and immune complexes will ameliorate the symptoms of rheumatoid arthritis.Type: ApplicationFiled: July 30, 2010Publication date: November 25, 2010Inventors: HENRY J. SMITH, James R. Smith
-
Publication number: 20100247650Abstract: This invention uses “targeted apheresis” to treat pregnant women who are at risk of developing eclampsia. “Targeted Apheresis” is a process whereby the sFlt-1 receptors responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing either immobilized PIGF, and/or through a cartridge containing immobilized anti-sFlt-1 antibody. The sFlt-1 receptor is bound out and the cleaned blood is returned to the patient Removal of circulating sFlt-1 receptors will diminish the risk of developing eclampsia during pregnancy.Type: ApplicationFiled: March 31, 2009Publication date: September 30, 2010Inventors: Henry J. Smith, James R. Smith
-
Patent number: 7777006Abstract: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.Type: GrantFiled: December 31, 2002Date of Patent: August 17, 2010Assignee: CSL Behring L.L.C.Inventors: Scott M. Kee, Paul I. Cook, James R. Smith, Robert Kling, Scott A. Fowler, David Weber
-
Publication number: 20100098698Abstract: This invention uses “targeted apheresis” to treat rheumatoid arthritis patients. “Targeted Apheresis” is a process whereby the RF and immune complexes responsible for causing the disease symptoms are selectively removed from the blood by passing the blood through a cartridge containing immobilized IgG. The RF and immune complexes are bound out and the cleaned blood is returned to the patient Removal of circulating RF and immune complexes will ameliorate the symptoms of rheumatoid arthritis.Type: ApplicationFiled: January 5, 2010Publication date: April 22, 2010Inventors: HENRY J. SMITH, James R. Smith
-
Patent number: 7225589Abstract: Presented is an anchor bolt placement and protection device to facilitate setting of anchor bolts in concrete to facilitate placement of a mud sill. It is important that the anchor bolts that secure a mud sill to a foundation be properly spaced from the outside edge of the foundation. In one embodiment there is provided a device having a tubular projection open at one end to receive the threaded end of an anchor bolt. Projecting integrally from the bottom open end of the tubular projection are two lateral projections. One is adapted to place an anchor bolt when a 2×4 mud sill is used. The second projection positions the anchor bolt at the proper distance to receive a 2×6 mud sill. A second embodiment is provided with a single lateral projection extending perpendicularly from the open bottom end of the tubular projection. The top surface of the lateral extension is provided with cross-ribs and indicia that indicate the proper placement of either a 2×4 or 2×6 mud sill.Type: GrantFiled: December 31, 2002Date of Patent: June 5, 2007Inventor: James R. Smith
-
Patent number: 6818215Abstract: Polyclonal and monoclonal antibodies that specifically bind senescent cell derived inhibitor protein (SDI-1), cell lines that produce such monoclonal antibodies, and the use of such antibodies are disclosed.Type: GrantFiled: December 7, 2001Date of Patent: November 16, 2004Inventors: James R. Smith, Asao Noda, Guy Adami
-
Publication number: 20040146514Abstract: This invention describes a method whereby antitumor antibodies obtained from different species and directed against a variety of antigens present in tumors can be used for immunotherapy of cancer. Some of these antibodies may have a direct inhibitory effect upon the tumor, or they may labeled with radionuclides or cytotoxic agents and used as “carriers” to transport the cytotoxic agent to the tumor where they will have maximum effect. By employing a succession of antitumor antibodies produced from different species the risk of the cancer patient developing an allergic reaction to the foreign antibodies is minimized.Type: ApplicationFiled: January 20, 2004Publication date: July 29, 2004Inventors: James R. Smith, Henry J. Smith
-
Publication number: 20040124143Abstract: A streamlined method for purifying alpha-1-antitrypsin (AAT) from an AAT-containing protein mixture, such as a Cohn fraction IV precipitate, is provided. In the method of the invention, contaminating proteins are destabilized by cleavage of disulfide bonds with a reducing reagent, such as a dithiol, which does not affect AAT. The destabilized proteins are then preferentially adsorbed on a solid protein-adsorbing material, without the addition of a salt as a precipitant. Separation of the solid adsorbent from the solution leaves a purified AAT solution that is directly suitable for chromatographic purification, without the need for extensive desalting as in prior art processes. A process incorporating this method, which provides pharmaceutical grade AAT in high yield on a commercial scale, is also described.Type: ApplicationFiled: December 31, 2002Publication date: July 1, 2004Inventors: Scott M. Kee, Paul I. Cook, James R. Smith, Robert Kling, Scott A. Fowler, David Weber
-
Patent number: 6756091Abstract: A lightweight flywheel containment composed of a combination of layers of various material which absorb the energy of a flywheel structural failure. The various layers of material act as a vacuum barrier, momentum spreader, energy absorber, and reaction plate. The flywheel containment structure has been experimentally demonstrated to contain carbon fiber fragments with a velocity of 1,000 m/s and has an aerial density of less than 6.5 g/square centimeters. The flywheel containment, may for example, be composed of an inner high toughness structural layer, and energy absorbing layer, and an outer support layer. Optionally, a layer of impedance matching material may be utilized intermediate the flywheel rotor and the inner high toughness layer.Type: GrantFiled: May 10, 2000Date of Patent: June 29, 2004Assignee: The Regents of the University of CaliforniaInventor: James R. Smith
-
Publication number: 20030133971Abstract: The use of liposomal formulations, particularly formulations of positively charged and neutral lipids facilitates cellular uptake of SDI molecules. The transcription and/or expression of SDI-1-encoding nucleic acid molecules is facilitated by constructs that contain intervening untranslated regions.Type: ApplicationFiled: December 7, 2001Publication date: July 17, 2003Inventors: James R. Smith, Asao Noda, Guy Adami
-
Patent number: 6574748Abstract: In a data processing system with multiple processors, failing processors are replaced with spare processors. This allows the system to continue to operate without degradation. An intercept process is notified of a processor failure so that it can collect processor registers and states. If the registers and states are collected correctly, an indication is set that relief is possible. The intercept process notifies a service processor of the failure and then halts the failed processor. The service processor then notifies the operating system of the failure and that relief is possible. If fast relief is acceptable, a spare processor is initialized and resumes execution with the state and registers of the failed processor. A service processor modeling file controls the number of active and spare processors in a system. Spare processors sharing the same L2 cache with the failed processor are preferred as replacements.Type: GrantFiled: June 16, 2000Date of Patent: June 3, 2003Assignee: Bull HN Information Systems Inc.Inventors: Sidney L. Andress, Curtis D. Andes, Gerald E. Rightnour, James R. Smith